Precision radiation tackles lung tumors near vital airways

NCT ID NCT04925583

Ongoing Disease control Sponsor: University Hospital Heidelberg Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1 trial tests a special type of radiation therapy for lung tumors located very close to the windpipe or esophagus. Using real-time MRI guidance, doctors can adapt the radiation dose daily to target the tumor while sparing nearby organs. Up to 38 patients will receive one of four dose levels to find the safest highest dose. The study monitors for side effects over 12 months and checks for tumor return over 24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic body radiotherapy (SBRT) using a MR-linac system
What this could lead to: If successful, this could establish a safer way to deliver high-dose radiation to lung tumors that are hard to treat because they are near the windpipe or food pipe.
What could go wrong: This is a very early phase 1 trial with only 38 people, focused on finding the highest safe dose. It is not designed to prove the treatment works, and there are risks of lung, esophagus, or heart side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

University Hospital of Heidelberg, Radiation Oncology

Heidelberg, 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.